Grifols (NASDAQ:GRFS) Sees Strong Trading Volume – Should You Buy?

Shares of Grifols, S.A. (NASDAQ:GRFS) saw unusually-strong trading volume on Thursday . Approximately 1,622,142 shares traded hands during mid-day trading, an increase of 102% from the previous session’s volume of 804,488 shares.The stock last traded at $8.41 and had previously closed at $7.94.

Analyst Ratings Changes

Separately, Morgan Stanley began coverage on Grifols in a research note on Wednesday, February 12th. They set an “overweight” rating for the company.

Grifols Price Performance

The business’s fifty day moving average price is $7.37 and its 200 day moving average price is $8.09. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.26 and a quick ratio of 0.79. The stock has a market cap of $5.70 billion, a P/E ratio of 7.09 and a beta of 0.40.

Hedge Funds Weigh In On Grifols

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Creative Planning increased its holdings in shares of Grifols by 26.4% during the third quarter. Creative Planning now owns 17,319 shares of the biotechnology company’s stock worth $154,000 after buying an additional 3,614 shares in the last quarter. Signaturefd LLC grew its position in Grifols by 66.2% during the 3rd quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company’s stock worth $48,000 after acquiring an additional 2,153 shares during the last quarter. International Assets Investment Management LLC acquired a new position in Grifols in the 3rd quarter worth about $1,700,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of Grifols by 63.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 23,464 shares of the biotechnology company’s stock valued at $208,000 after purchasing an additional 9,130 shares in the last quarter. Finally, US Bancorp DE boosted its stake in shares of Grifols by 12.3% during the third quarter. US Bancorp DE now owns 20,663 shares of the biotechnology company’s stock valued at $183,000 after purchasing an additional 2,256 shares in the last quarter.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.